Therapy-related acute myelogenous leukemia (t-AML) is an important late adverse effect of alkylator chemotherapy. Susceptibility to t-AML has a genetic component, yet the specific genetic variants that influence susceptibility are poorly understood. We analyzed an F 2 intercross (n=282 mice) between mouse strains resistant or susceptible to t-AML induced by the alkylator, ethyl-N-nitrosourea (ENU) to identify genes that regulate t-AML susceptibility. Each mouse carried the hCG-PML/RARA transgene, a well-characterized initiator of myeloid leukemia. In the absence of ENU treatment, transgenic F 2 mice developed leukemia with higher incidence (79.4% vs. 12.5%) and at earlier time points (108 days vs. 234 days) than mice in the resistant background. ENU treatment of F 2 mice further increased the incidence (90.4%) and
INTRODUCTION
Approximately 5-10% of all acute myeloid leukemia (AML) cases are the result of prior genotoxic therapy. 1, 2 Like other secondary malignancies, therapy-related AML (t-AML) responds poorly to treatment and the median survival is only 6-12 months. 2, 3 The poor prognosis and the iatrogenic nature of t-AML provide impetus for determining risk factors that contribute to t-AML susceptibility. Based on the type of preceding treatment, t-AML can be broadly classified as alkylator-associated or topoisomerase II inhibitor-associated. Alkylatorassociated t-AML generally arises after a latency of 3-5 years and frequently evolves from a myelodysplastic syndrome (MDS) 4 . Alkylating agents such as nitrosoureas and cyclophosphamide are widely used in the treatment of solid tumors (e.g., breast, ovarian, and lung carcinomas) as well as leukemias and lymphomas. Because therapeutic options exist for most patients, personalized treatment plans based on t-AML risk factors could significantly reduce the incidence of this serious adverse outcome.
There are several known non-genetic risk factors for t-AML. Chemotherapy dose is correlated with risk of t-AML. 5 Long-term, low dose alkylator treatment and short-term, high-dose treatment (in the context of stem cell transplantation) confer the greatest risk of t-AML. [5] [6] [7] There is also an association with primary cancer type. In a large single institution series, hematologic malignancies (e.g., non-Hodgkin's lymphoma, Hodgkin's disease, myeloma, acute lymphoblastic leukemia) comprised 171/306 (56%) of primary malignancies preceding t-AML. 8 However, there are documented cases of t-AML arising from alkylator treatment of a wide variety of tumors. Age is another important risk factor. The most recent evidence indicates that in the context of stem cell transplantation, patients over 40 are at increased risk of developing t-AML. 9 In addition to these risk factors, several lines of evidence suggest there is a genetic component to t-AML susceptibility. First, a higher incidence of cancer is found in first degree relatives of patients with secondary AML compared to relatives of patients with de novo AML. 2 Also, some familial forms of cancer predisposition confer an increased risk of t-AML (e.g.
Neurofibromatosis type 1 and Li Fraumeni Syndrome). 10, 11 These rare familial syndromes cause highly penetrant disease but account for a small number of t-AML cases. In addition, association studies have suggested that common polymorphisms in drug metabolism genes (e.g., cytochrome p450 enzymes and phase II conjugation enzymes) and DNA repair pathways can contribute to t-AML susceptibility (reviewed by Seedhouse and Russell 12 ). In two studies, the CYP3A4*1B allele was underrepresented in t-AML patients compared to patients with de novo AML 13 or with a control cohort. 14 However, other studies of CYP3A4*1B comparing children treated for ALL who did or did not develop t-AML 15 and comparing t-AML cases with normal controls 16 showed no association. The results from studies of several other candidate genes are similarly mixed and a comprehensive understanding of the important genetic factors influencing t-AML susceptibility remains elusive.
Because susceptibility factors for t-AML are largely unknown, an unbiased, genome-wide screen could identify important targets for further study. Inbred mice provide a powerful platform for identifying the genetic basis of complex traits. We previously screened 20 inbred strains and reported that susceptibility to t-AML in mice is heritable. 17 In that study, SWR/J mice were found to be highly susceptible to t-AML, whereas C57BL/6J and C3H/HeJ mice were resistant. 17 Based on these results, we designed an F 2 intercross to define regions of the genome important for t-AML susceptibility in mice.
MATERIALS AND METHODS

Mice
Transgenic hCG-PML/RARA (PR) mice were maintained in a C57BL/6J x C3H/HeJ F 1 (B6C3F1) background. 18 Genotyping was performed as previously described. 19 SWR/J mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in a specificpathogen-free facility. All studies were conducted with the approval of the Animal Studies Committee at Washington University School of Medicine.
Mutagenesis protocol
Ethyl-N-nitrosourea (ENU; Sigma) was administered at 9 and 10 weeks of age (200 mg/kg IP, total dose), as previously described. 17 Mice were pretreated with hydrocortisone (2.5 mg IP qod
x 3) at 8 weeks of age (i.e., 1 week prior to ENU treatment) to decrease the incidence of thymic lymphomas.
Hematologic analysis
Mice were sacrificed when moribund, or when they reached 14 months of age. Post-mortem analysis included spleen weight, complete blood counts, flow cytometric analysis and histological evaluation of blood and bone marrow smears. Complete blood counts were obtained with a Forcyte veterinary cell counter (Oxford Sciences, Inc., Oxford, CT). For flow cytometry, bone marrow and spleen cells were stained with directly conjugated antibodies to B220, CD3, CD45, c-kit, GR1, CD34, CD4, and CD8 (BD Biosciences, San Jose, CA). Scatter gated events (10,000) were acquired on a FACScan (BD Biosciences) and analyzed with FlowJo software (ver 4.5.1, Treestar, Inc., Ashland, OR). Flow cytometry data is reported as mean ± SD. For histologic evaluation, tissues were fixed in 10% formalin and embedded in paraffin. 5 micron sections were stained with H&E and reviewed by a veterinary pathologist.
Peripheral blood, bone marrow smears, and spleen touch preps were stained with May-Grünwald/Giemsa and manually scored.
Survival analysis
The cumulative probability of leukemia-free survival was estimated by the Kaplan-Meier method.
Mice were censored at the time of death if post-mortem analysis did not demonstrate leukemia (e.g., lymphoma, myeloproliferative disorder without features of acute leukemia, or no significant abnormalities at the time of sacrifice). Differences in survival between cohorts was assessed by the log rank test.
SNP selection
Custom oligonucleotide pools (Illumina, San Diego, CA) were designed for 384 informative SNPs chosen from the Wellcome Trust -CTC mouse genotype set (http://www.well.ox.ac.uk/mouse/INBREDS/) to provide a 4 cM resolution map across the mouse genome (Table S1 ). All selected SNPs are polymorphic between SWR/J and B6C3F1 and monomorphic between C57BL/6J and C3H/HeJ so that the SWR/J allele can be unambiguously identified at each locus. Tail DNA prepared from the parental (SWR/J and B6C3F1), F 1 (n=10) and F 2 mice (n=282) were arrayed with replicates in 96-well plates. Using the GoldenGate protocol, these samples were amplified in an allele-specific manner, and hybridized to Sentrix arrays (Illumina). Genotype calls were made using BeadStudio software (Illumina). Twenty-seven of the 384 SNPs were excluded for poor call rates leaving 357 markers for analysis. All markers were tested for deviation from Hardy-Weinberg (HW) proportions using a chi-square test with 1 degree of freedom. Markers diverging from HW were checked for excessive recombination and none was found.
Genetic map
R/QTL 20 was used to detect possible genotyping errors and to estimate the map distances in centimorgans (cM). Because all individuals were male, the map distances for the X chromosome were calculated by counting the recombinants for each individual and converting them to map distances. Genotypes with error LOD scores greater than 4 were treated as missing and imputed using methods from Haley and Knott. 21 The average inter-marker map distance is 3.89 cM. The largest inter-marker distance is 46 cM on chromosome 10 corresponding to the largest physical distance between markers (51.8 Mb). The map distance was similar to that found in the Oxford Wellcome Trust database. The genotypes at each marker were coded as 1 (SWR/J allele homozygote), 0 (heterozygote) and -1 (B6C3F1 allele homozygote). Only transgene-positive mice were used in the study, resulting in a selection of only a portion of the variation in the chromosome immediately around the transgene in chromosome 2. Consequently, QTLs near this transgene integration site will not be detected in this analysis.
QTL analysis
We searched for QTLs in the F 2 mice associated with three quantitative traits: leukemia-free survival, white blood cell count (WBC), and spleen weight. The QTLs were mapped using interval mapping methods as first proposed by Lander and Botstein. 22 Intervals were imputed for the autosomal data 21 and the X chromosome 23 every 1 cM between the 357 observed markers, resulting in 1658 observed and imputed locations across the genome (physical and genetic map distances provided in Table S1 ). All analyses were performed in R (http://www.rproject.org). WBC and spleen weight were log transformed and analyzed with standard linear regression while the survival data was analyzed using the Cox Proportional Hazards Model 24 by implementing the coxph function from the Survival package in R (http://www.rqtl.org).
Models
Four models were used to test our hypothesis that genotype influences t-AML susceptibility.
For each model, the additive genotypic value (a; half the mean difference between the homozygotes) and the dominance genotypic value (d; deviation of the heterozygote mean from the midpoint of the homozygotes, commonly described as interaction within a locus) were calculated. A large 'a' signifies a large difference between homozygotes. The dominance ratio (calculated as d/a) signifies no dominance if |d/a| is <<1, complete dominance if |d/a| is ~1, and overdominance if |d/a| is >>1. The covariate model pools a and d across treatment groups. A significant result indicates genotypic effects independent of treatment status. The interaction model tests for interaction between treatment status and genotypic effects. A significant result implies a genotypic effect that is different in treated vs. untreated mice. The final two models, +ENU and -ENU, examine each treatment group separately and were used only for interpretation of the full interaction model. Significance thresholds at genome-wide and chromosome-wide levels were calculated by performing 1000 permutations of the phenotypic data while leaving the genotypic data intact. Thresholds for all four models were essentially the same for each phenotype; therefore, the average threshold of all four models was used for each phenotype. Averaging the thresholds did not add or eliminate any QTLs. The significance thresholds for the survival data were calculated from the covariate model combined for both groups and also within the untreated group.
Gene List
The 1 LPR (likelihood probability ratio) confidence interval was determined for all QTL peaks.
The interval was then converted from the genetic map to physical map location using the known physical location of observed SNPs. When 1 LPR confidence intervals ended at an imputed location, the physical location of the imputed point was approximated by using the observed SNPs flanking the imputed location to create a linear transform from the genetic to the physical map. The list of genes was generated by searching physical map intervals using the Ensembl Biomart search function (http://www.ensembl.org/biomart/martview/). For prioritization purposes, genes within QTLs were queried for Medline citations using the MeSH terms "myelodysplastic syndrome," "leukemia, myeloid," "DNA repair," "metabolic detoxication, drugs," and "alkylating agents." The number of citations was summed to generate a "MeSH score" for each gene.
RESULTS
SWR/J alleles accelerate development of leukemia initiated by PML/RARA.
In a screen for susceptibility to alkylator-induced myeloid leukemia in mice, we previously identified several sensitive (e.g., SWR/J) and resistant (e.g., C57BL/6J, C3H/HeJ) strains. 17 To identify regions of the SWR/J genome that influence t-AML susceptibility, we designed an F 2 intercross experiment. We "sensitized" the screen towards development of myeloid leukemia by breeding in the hCG-PML/RARA (PR) transgene. The PR transgene places the bcr-1 isoform of the t(15;17) PML/RARA fusion cDNA under the regulatory control of the human cathepsin G promoter. 18 All PR + mice develop a myeloproliferative disorder (MPD) characterized by modest splenomegaly and an increase in the proportion of mature and immature myeloid cells in the peripheral blood and bone marrow. 18 Additionally, MPD evolves into acute leukemia in 6-30% 18,25 of PR + mice after a latency of 6-13 months. 18 The long latency and low penetrance of AML suggests that while PR is sufficient for MPD, transformation to AML requires additional cooperating mutations. We used this potent initiator of myeloid leukemia to probe for germline alleles that influence susceptibility to t-AML. Parental SWR/J and PR + B6C3F1 mice were crossed to create the F 1 generation. PR + and PR -F 1 littermates were bred and single transgene positive male F 2 mice were treated (n=141) or untreated (n=141) with ENU and sacrificed and analyzed when moribund or when they reached 14 months of age. Only male mice were included, since we previously observed a high incidence of ENU-induced uterine tumors in several strains leading to loss of power to detect myeloid leukemias with longer latency. 17 A separate cohort of B6C3F1 transgene positive male mice (n=24 untreated, n=21 ENU treated) was generated for comparison.
Consistent with previous reports, 18 all PR + B6C3F1 mice developed MPD and 12.5% progressed to AML ( Figure 1 , Table 1 ). In contrast, untreated PR + F 2 mice developed AML at a higher frequency (79.4%, p<0.0001) and shorter latency (108 days vs. 234 days) and had significantly reduced survival (p<0.0001 by logrank) with a median survival of 254 days. These results suggest that SWR/J alleles increase susceptibility to PR-initiated leukemia and confirm our prior observation that the SWR/J genome contains factors that predispose mice to myeloid leukemia.
The leukemias detected in untreated F 2 mice were characterized by splenomegaly, leukocytosis, anemia, and thrombocytopenia (Table 1) . Flow cytometric analysis demonstrated that, compared to untreated non-leukemic F 2 mice, untreated leukemic F 2 mice had a higher proportion of c-kit+CD45+ cells ( Table 2) . Splenic architecture was effaced by infiltrating neoplastic cells. In summary, the phenotype of leukemias arising in untreated F 2 PR + mice strongly resembles the acute leukemia with promyelocytic features previously described in PR + B6C3F1 mice. 18 
ENU treatment interacts with genotype to promote leukemogenesis
ENU-treated PR + B6C3F1 mice developed leukemia at a higher rate than untreated littermate PR + mice (57.1% vs. 12.5%, P=0.0036) and had significantly shorter survival (P<0.0001), although their survival was not significantly different from untreated F 2 mice (P=0.34) ( Figure 1 , Table 1 ). This suggests that ENU treatment of PR + mice in the resistant background and exposure to SWR/J alleles are roughly equipotent, though not necessarily mechanistically equivalent, in promoting leukemia.
ENU also interacts with SWR/J alleles in F 2 mice to increase leukemia incidence. Compared to treated B6C3F1 mice, treated F 2 mice develop leukemia at much higher incidence (90.4% vs. 57.1%, P<0.0001), with shorter latency (111 vs. 199 days), and shorter median survival (171 vs. 233 days). Similarly, treated F 2 animals developed leukemia with a higher incidence than untreated F 2 animals (90.4% and 79.4%; P<0.01) and had decreased median survival (171 vs.
days).
The phenotype of leukemia in treated and untreated F 2 mice was similar, although ENU-treated leukemic F 2 mice had higher spleen weight, higher WBC, lower hemoglobin, and lower platelet counts ( Table 1 ). Compared to F 2 treated non-leukemic mice, F 2 treated leukemic mice had an increased proportion of c-Kit+CD45+ cells (22.74% ± 15.75 vs. 6.80% ± 6.13; P=0.047) in the bone marrow, decreased B220+ cells (20.98% ± 11.30 vs. 47.31% ± 15.12; P=0.0002) and decreased CD3+ cells (3.50% ± 2.92 vs. 10.39% ± 5.47; P<0.0001) in the spleen. The leukemic cells in treated and untreated F 2 mice had similar morphology in peripheral blood, bone marrow, and spleen (not shown).
T-cell lymphomas were detected in a small number of ENU-treated mice (n=3 B6C3F1, n=6 F 2 )
These mice had a high percentage of immature lymphoid cells in the peripheral blood and a monomorphic population of small lymphocytes in the bone marrow ( Figure 2 ). Splenic architecture was effaced by an infiltrate of immature lymphoid cells. Flow cytometric analysis demonstrated a large population of CD4+CD8+ cells in both the spleen (38.97% ± 28.18) and bone marrow (data not shown).
QTL analysis reveals significant peaks for survival, spleen weight and WBC
Since survival in this leukemia model was significantly influenced by genetic background, we performed genotype:phenotype association mapping to identify regions of the mouse genome containing genes that regulate this trait. In addition to survival, we sought to determine if spleen weight and WBC were influenced by genotype. These parameters were included because splenomegaly 26 and high WBC 27 are markers of poor prognosis in human AML. Thirteen QTLs were found that affected the traits of interest in the F2 population, including five loci affecting leukemia-free survival (MleuX.Y where X specifies chromosome and Y specifies the QTL on the chromosome), five affecting spleen weight (SplX.Y), and three affecting white blood cell count (WbcX.Y) ( Table 3) . Two QTLs (Mleu1.1 and Spl11.1) were significant at the genome-wide threshold; the remainder were significant at the chromosome threshold. Seven QTLs provided evidence for significant genotype by treatment interaction indicating that their effects were either restricted to the ENU-treated population (Mleu1.1, Wbc1.1, Wbc15.1 For the survival QTLs, all significant additive effects, except for Mleu1.1 (Figure 3 The three white blood cell count QTLs map to chromosomes 1 (Wbc1.1), 15 (Wbc15.1), and 19 (Wbc19.1). At Wbc1.1, the SWR/J allele leads to a reduction in WBC count in ENU-treated animals but has no effect in untreated animals. This difference in gene effects between treated and untreated groups is also statistically significant. At Wbc15.1, the SWR/J allele leads to higher WBC count in the treated group, but has no effect in the untreated group. At Wbc19.1, at the distal end of chromosome 19, the SWR/J allele leads to higher WBC count in both the treated and untreated populations (Figure 3 ).
Since the total number of genes contained within these QTLs is large (3,474 genes in 13 QTLs), we used a bioinformatic strategy (described in Methods) to systematically identify the subset of genes with known connections to myeloid leukemogenesis. The most frequently cited genes (Table 4 ) represent high priority candidate t-AML susceptibility factors.
DISCUSSION
Studies in mice 17, 28 and humans 29,30 support the concept that susceptibility to myeloid leukemia has a genetic component. In addition, environmental factors (e.g., genotoxic therapy) and gene by environment interactions contribute to t-AML susceptibility. Intermediate phenotypes relevant for t-AML include the response to DNA damage, the efficiency of drug metabolism, and/or the frequency of cells vulnerable to transformation. Correspondingly, QTLs influencing stem cell number, 28 and genes involved in DNA repair and drug metabolism [12] [13] [14] have been associated with t-AML susceptibility. Human studies have identified a limited number of genetic variants that are more prevalent in affected individuals, but due to the complex nature of t-AML susceptibility, it is likely that important genetic determinants have not yet been identified. Inbred mouse strains provide an experimental system for whole genome scans using a tractable number of animals. This approach has the potential to identify contributors to t-AML susceptibility (or other complex traits) that would not have been selected a priori for a candidate gene approach. We previously reported that susceptibility to alkylator-associated AML in inbred mice is a heritable trait. 17 Here we report the results of an F 2 intercross (sensitized by including the hCG-PML/RARA transgene) between strains of mice previously identified as susceptible (SWR/J) or resistant (C57BL/6J and C3H/HeJ) to developing alkylator-induced AML.
Transgenic F 2 mice were highly susceptible to leukemia with (90.4% incidence) or without (79.4%) alkylator therapy, confirming the original observation that the SWR/J genome contains alleles that predispose mice to myeloid malignancy. A genome-wide analysis in this cohort identified thirteen quantitative trait loci (QTLs) significantly associated with survival, spleen weight, or WBC. suggesting that most of the variance seen in these models cannot be explained by a single QTL. The three survival QTLs detected in the ENU-treated model account for 30% of the variance seen in this model. The remaining variance is attributable to other environmental causes, or genes with effect sizes too small for our study to detect.
As predicted, additive genotypic values for most of the QTLs we detected suggest that SWR/J alleles promote phenotypes associated with a worse outcome in this leukemia model (i.e., decreased survival and increased WBC). This is consistent with our original observation that SWR/J mice are more susceptible to ENU-induced myeloid malignancies (AML, MDS, granulocytic sarcoma). 17 However, the additive genotypic values for one survival QTL (Mleu1.1), three spleen weight QTLs (Spl7.1, Spl11.2, and Spl16.1) , and one WBC QTL (WBC1.1) indicate that SWR/J alleles at these QTLs lead to increased survival, and decreased spleen weight or WBC. Several plausible explanations for these counterintuitive results are possible. With respect to survival, t-AML susceptibility is a complex trait, so while the overall effect of the SWR/J background increases susceptibility, it is possible that some individual genes within SWR/J lead to enhanced survival. Three of five spleen weight QTLs suggested that lower spleen weight was associated with a homozygous SWR/J genotype at those QTLs.
For these QTLs, it is possible that once the leukemic transformation has occurred, SWR/J homozygous mice succumb more quickly than their B6C3F1 counterparts, leaving less time for infiltration of the spleen before sacrifice. One could envision a similar scenario for WBC1.1. A final explanation may be that epistatic interactions between SWR/J and B6C3F1 alter the expected phenotype of F 2 mice; effectively giving the appearance that SWR/J alleles enhance survival (or spleen weight), though the effect is primarily due to interactions between unlinked SWR/J and B6C3F1 genes.
Approximately 5% of human AML cases with t(15;17) arise following chemotherapy, 31 including alkylator treatment in the majority of patients, 32 establishing the clinical relevance of this model.
However, a potential caveat of the design is that it may be biased to detect QTLs that interact primarily with PML/RARA. Since all mice in the present study were transgene positive, we cannot directly determine the impact of PML/RARA on these results. However, the large effect of ENU in the F 2 population and the fact that most of the QTLs detected are treatmentdependent suggest that these findings are largely alkylator-associated and not solely PML/RARA-dependent. In addition, we have confirmed in a larger cohort our previous observation that non-transgenic SWR/J mice are susceptible to ENU-induced myeloid malignancies (Walter, MJ, et. al., manuscript in preparation). Therefore, the susceptibility loci mapped in this F 2 cross are likely to be relevant for AML pathogenesis in the presence or absence of PML/RARA.
As expected in this F 2 intercross, the QTL regions we describe are large and contain many genes with established roles in leukemogenesis. Fine-mapping these QTLs will likely uncover other genes with no known connections to AML biology. Candidate genes will require further study to determine their contribution to the QTL phenotypes and their role in t-AML susceptibility. Bcl2 (located 144 Kbp from the peak of Mleu1.1) is a particularly interesting candidate since high BCL2 expression is associated with poor survival in patients with AML. 33 Of note, a genetic interaction between Bcl2 and PML/RARA has been demonstrated previously. 34 Co-expression of Bcl2 and PML/RARA from the MRP8 promoter in transgenic mice produced a greater impairment in myeloid maturation at the promyelocyte stage and decreased median time to leukemia (127 vs. 257 d) compared to mice transgenic for MRP8-PML/RARA alone. 34 This provides strong circumstantial evidence suggesting that Bcl2 may be the quantitative trait gene driving Mleu1.1, the most significant survival QTL detected in our F 2 intercross. Since ENU triggers an apoptotic response in a number of tissues, [35] [36] [37] differences in the Bcl2 coding sequence or expression levels between SWR/J and B6C3F1 might affect the response to apoptotic signals in early myeloid cells. Altered Bcl2 expression could affect the balance between pro-and anti-apoptotic signals, thereby promoting survival of cells that have accumulated significant DNA damage. Such cells may be more prone to subsequent mutations that contribute to leukemogenesis.
Discovering the specific genetic variations that underlie these QTLs may provide information that can be used to predict t-AML susceptibility prospectively in patients. Such knowledge would be a valuable tool in designing treatments to minimize the risk of adverse outcomes such as t-AML. Conflict-of-interest disclosure: The authors declare no competing financial interests. Mean (SD). ENU, ethyl-N-nitrosourea. * p<0.05, ** p<0.01, *** p<0.001 for two-tailed t-tests comparing non-leukemic to leukemic mice. # median survival not reached. Y where X is the chromosome and Y is the number along the chromosome), spleen weight (SplX.Y), and white blood cell count (WbcX.Y). LPR CI, Likelihood Probability Ratio Confidence Interval (**significant at the genome-wide threshold, *significant at chromosome-wide threshold); R 2 = proportion of variance for the model. Gene effects are 'a' for the additive genotypic value, 'd' for the dominance genotypic value, (SE) indicates standard error of the estimate, values for 'a' and 'd' in bold are significant at p = 0.05. Fas (TNF receptor superfamily member) Mleu19. 1 6 All genes within QTLs were queried for Medline citations using the MeSH terms "myelodysplastic syndrome," "leukemia, myeloid," "DNA repair," "metabolic detoxication, drugs," and "alkylating agents." Citations for each gene were summed to generate a "MeSH score." Genes with greater than five citations are shown here. Figure 3 
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